Xerava

(Eravacycline)

Phase 3Small molecule

TTetraphase Pharmaceuticals, Inc

Xerava is one of 51 small molecule programs targeting Liver. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[3][1]

Indication

LiverNot yet recruiting

Complicated Intra-Abdominal InfectionsCompleted

NeutropeniaRecruiting

LiverPhase 3

Not yet recruiting

Complicated Intra-Abdominal InfectionsPhase 3

Completed

NeutropeniaPhase 2

Recruiting

Competition

Competitive Landscape

32 competitors in Neutropenia

#DrugCompanyPhaseTrials

Cipro

Bayer

Approved

4 2

Maxipime

Pfizer

Approved

2 3

Merrem

BB. Braun Medical Inc.

Approved

4 4

Levaquin

WWim Janssens

Approved

2 5

Abelcet

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

1 6

Mycamine

BBaxter Healthcare Corporation

Approved

1 7

Avycaz

PPhiladelphia Eye Associates

Approved

1 8

Amikin

IInsmed Incorporated

Approved

1 9

Mozobil

GGenzyme, a Sanofi Company

Approved

—10

Peridex

DDexcel Pharma Technologies Ltd.

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Post-ApprovalRecruiting

Study completion

NCT06440304

Q1 2028

Phase 2Recruiting

Neutropenia

NCT05537896

Q1 2029

Phase 2Recruiting

Complicated Intra-Abdominal Infections

NCT06794541

Q3 2029

Phase 3Not yet recruiting

Liver

NCT07759453

Clinical

Trials by Indication[1]

Complicated Intra-abdominal Infections3 trials

A Study to Evaluate the Safety and Tolerability of Eravacycline in Pediatric Patients Aged 8 to 17 With Complicated Intra-abdominal Infections (cIAI)

Recruiting·TTetraphase Pharmaceuticals, Inc·Phase 2·NCT06794541·35 enrolled

Efficacy and Safety Study of Eravacycline Compared With Meropenem in Complicated Intra-abdominal Infections

Completed·TTetraphase Pharmaceuticals, Inc·Phase 3·NCT02784704·500 enrolled

Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Complicated Intra-abdominal Infections

Completed·TTetraphase Pharmaceuticals, Inc·Phase 3·NCT01844856·541 enrolled

Combination Therapy2 trials

Efficacy and Safety of the Combination Therapy Based on Eravacycline in Immunocompromised Hosts With MDROS Infection

Unknown status·SSichuan Provincial People's Hospital··NCT06223100·100 enrolled

Eravacycline Combination Therapy for MRAB

Unknown status·FFujian Medical University Union Hospital··NCT06282835·20 enrolled

Urinary Tract Infection2 trials

Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections

Completed·TTetraphase Pharmaceuticals, Inc·Phase 3·NCT03032510·1,205 enrolled

Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections

Completed·TTetraphase Pharmaceuticals, Inc·Phase 3·NCT01978938·908 enrolled

Hepatic Function1 trial

A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With Impaired Hepatic Function and Healthy Subjects

Completed·TTetraphase Pharmaceuticals, Inc·Phase 1·NCT02135302·24 enrolled

Neutropenia1 trial

Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia

Recruiting·WWest Virginia University·Phase 2·NCT05537896·55 enrolled

3 more indications

End-Stage Renal Disease1 trial

A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With End Stage Renal Disease and Healthy Subjects

Completed·TTetraphase Pharmaceuticals, Inc·Phase 1·NCT02135276·12 enrolled

Liver1 trial

Targeted Versus Standard Peri-operative Antibiotic Prophylaxis in Patients Colonized With Carbapenemase-producing Enterobacterales Undergoing Liver Transplantation: a Stepped Wedge Cluster Randomization Trial

Not yet recruiting·IIRCCS Azienda Ospedaliero-Universitaria di Bologna·Phase 3·NCT07759453·168 enrolled

Unspecified2 trials

Therapeutic Options for CRAB

Recruiting·—·Phase 4·NCT06440304·108 enrolled

A Safety and PK Study of IV Eravacycline

Completed·TTetraphase Pharmaceuticals, Inc·Phase 1·NCT03696550·19 enrolled

Regulatory

FDA Approval Timeline[4]

Aug 27, 2018

XERAVA

NDA NDA211109

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for Eravacycline. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Eravacycline compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Eravacycline. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA211109). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Xerava. U.S. Food & Drug Administration.
[6]
SEC EDGAR — Tetraphase Pharmaceuticals, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: TTetraphase Pharmaceuticals, Inc

Patent Landscape[5]

Patent Cliff

Aug 7, 2029

Earliest patent expiration — generic entry possible after this date

Patent #Expires

8796245Aug 7, 2029

8906887Dec 28, 2030

11578044Oct 19, 2037

10961190Oct 19, 2037

Xerava

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q1 2028

Q1 2029

Q3 2029

Trials by Indication[1]

Complicated Intra-abdominal Infections3 trials

Combination Therapy2 trials

Urinary Tract Infection2 trials

Hepatic Function1 trial

Neutropenia1 trial

End-Stage Renal Disease1 trial

Liver1 trial

Unspecified2 trials

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Patent Landscape[5]

Related News